The POWERWAND range of products are clinically differentiated vascular access solutions, supported by nine peer-reviewed papers and nine scientific posters. Bloodstream infections are a known risk associated with vascular access catheters. Conclusions from recent clinical studies show no occurrence of bloodstream infections associated with use of the POWERWAND products. Combined, these studies have a total of 35,000 catheter days without bacterial infections.1-3
The POWERWAND range of products offers value to healthcare providers looking to offer quality care for their patients. When combined with Smiths Medical’s already strong performing Jelco IV catheter and Port-A-Cath products, Smiths Medical now offers clinicians more solutions to treat their patients through a broader portfolio.
“Smiths Medical’s acquisition of Access Scientific enhances our commitment to patient care and outcomes, driving category leadership in our existing vascular access portfolio,” said JehanZeb Noor, Smiths Medical CEO. “We believe this acquisition enhances our position as a trusted medication management solutions company. During this time of uncertainty, we feel privileged to offer our customers on the frontlines more choices for treating their patients.”
1 Devries M, Lee J, Hoffman L. Infection free midline catheter implementation at a community hospital (2 years). American Journal of Infection Control. 2019;47(9):1118-1121.
2 Caparas JV, Hung H-S. Vancomycin Administration Through a Novel Midline Catheter: Summary of a 5-Year, 1086-Patient Experience in an Urban Community Hospital. Journal of the Association for Vascular Access. 2017;22(1):38-41.
3 Pathak R, Patel A, Enuh H, Adekunle O, Shrisgantharajah V, Diaz K. The Incidence of Central Line–Associated Bacteremia After the Introduction of Midline Catheters in a Ventilator Unit Population. Infectious Diseases in Clinical Practice. 2015;23(3):131-134.